Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Trevi Therapeutics, Inc. (TRVI) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "Trevi Therapeutics Announces Second Quarter 2023 Financial Results and Provides Business Update Plans to initiate three clinical studies in chronic cough indications for later this year remain on track Data from Phase 2 CANAL trial of chronic cough in patients with idiopathic pulmonary fibrosis published in NEJM Evidence Management to host a conference call and webcast today at 4:30 p.m. EDT New Haven, Conn., August 10, 2023 – Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis , other chronic cough indications, and prurigo nodularis, today announced financial results for the quarter ended June 30, 2023, as well as provided business updates. ..."
05/11/2023 8-K Quarterly results
Docs: "Trevi Therapeutics Announces First Quarter 2023 Financial Results and Provides Business Update Initiating three clinical studies in chronic cough indications later this year Received Notice of Allowance for key U.S. patent for the use of oral nalbuphine ER for the treatment of chronic cough in idiopathic pulmonary fibrosis Management to host a conference call and webcast today at 4:30 p.m. EDT New Haven, Conn., May 11, 2023 – Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis , other chronic cough indications and prurigo nodularis , today announced financial results for the quarter ended March 31, 2023, as well as provided business updates. ..."
11/10/2022 8-K Quarterly results
Docs: "Trevi Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update Management to host a conference call and webcast today at 4:30 p.m. EDT"
08/11/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
11/10/2021 8-K Quarterly results
Docs: "Trevi Therapeutics Announces Third Quarter 2021 Financial Results and Business Update Phase 2b/3 PRISM Trial Approximately 90% Enrolled, Top-Line Data Readout Expected First Half of 2022"
08/12/2021 8-K Quarterly results
Docs: "Phase 2b/3 PRISM trial of Haduvio for severe pruritus in patients with PN o Approximately 285, or 80%, of planned subjects have enrolled ▪ Enrollment expected to be completed by the end of 2021 o Top-line data readout expected in the first half of 2022 • Phase 2 CANAL trial of Haduvio for chronic cough in patients with IPF o Ongoing recruitment and screening taking place at multiple sites in the UK o Top-line data readout expected in the first half of 2022 • Expanded leadership team to support the growth of the Company Second Quarter 2021 Financial Highlights Cash position: As of June 30, 2021, the Company had total cash and cash equivalents of $36.4 million, compared to $45.0 million as of December 31, 2020. Research and development expenses: R&D expenses for the second quarter of 2..."
05/13/2021 8-K Quarterly results
11/12/2020 8-K Quarterly results
Docs: "Phase 2b/3 PRISM trial of Haduvio for severe pruritus in patients with prurigo nodularis: The Company has enrolled approximately 190 subjects in the trial and reaffirms its guidance that it expects to complete enrollment in the third quarter of 2021 and to report top-line data in the fourth quarter of 2021. • Phase 2 trial of Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis : The Company resumed screening and enrolling patients in the trial following the pause in the trial due to COVID-19. The Company amended the study protocol to require fewer in-person visits by subjects as well as fewer procedures in order to facilitate the completion of the trial in an at-risk patient population for COVID-19. Additionally, the Company is assessing additional study sites i..."
08/13/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
Docs: "Phase 2b/3 PRISM trial of nalbuphine ER for severe pruritus in patients with prurigo nodularis: The pace of enrollment in the PRISM trial has been impacted by the COVID-19 pandemic with new patient screening and most patient enrollment temporarily halted. Patient screening restrictions have been lifted in the United States and are in the process of being lifted in Europe. We expect many of our sites will restart patient screening and enrollment throughout May and June 2020. The protocol for the PRISM trial provides for a sample size re-estimation analysis once approximately 50% of the patients in the trial are evaluable for the primary endpoint. In light of the pandemic-related delays, we have decided to conduct the SSRE analysis once approximately 45% of the patients in the trial are eval..."
11/14/2019 8-K Quarterly results
08/12/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : August 12, 2019 Trevi Therapeutics, Inc. Delaware 001-38886 45-0834299 195 Church Street, 14 th Floor New Haven, Connecticut 06510 Registrant's telephone number, including area code: 304-2499 Not applicable",
"TREVI THERAPEUTICS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy